IMEIK(300896) 海通证券·2024-11-12 00:43Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company is a leading player in the medical aesthetics upstream sector, with a strong product portfolio and forward-looking demand insights [10] - Short-term performance growth has slowed due to external environmental pressures on consumer traffic and purchasing power [10] - Medium to long-term growth is expected as existing products expand indications and new products like botulinum toxin and weight-loss drugs gain approval [10] - The company is expected to benefit from domestic substitution and industry compliance trends, gaining market share in a stricter regulatory environment [10] Financial Performance - In the first three quarters of 2024, the company achieved revenue of RMB 2.376 billion, a YoY increase of 9.46%, and net profit attributable to shareholders of RMB 1.586 billion, a YoY increase of 11.79% [5] - Gross margin slightly decreased by 0.5 percentage points to 94.80% in the first three quarters of 2024 [6] - R&D expenses increased by 0.54 percentage points to 7.89% in the first three quarters of 2024 [7] - Non-GAAP net profit margin decreased by 3.5 percentage points to 61.46% in the first three quarters of 2024 [8] Product Pipeline and R&D - The company's R&D pipeline is progressing well, with new indications for existing products and new drugs entering clinical trials [8] - The company is expanding into more life science fields, including biopharmaceuticals and chemical drugs [8] Financial Forecasts - Revenue for 2024-2026 is forecasted to be RMB 3.188 billion, RMB 3.793 billion, and RMB 4.552 billion, with YoY growth rates of 11.1%, 19.0%, and 20.0% respectively [10] - Net profit attributable to shareholders for 2024-2026 is forecasted to be RMB 2.044 billion, RMB 2.388 billion, and RMB 2.773 billion, with YoY growth rates of 10.0%, 16.8%, and 16.1% respectively [10] Valuation - The company is valued at 30-35 times PE for 2025, corresponding to a reasonable market value range of RMB 71.7-83.6 billion and a reasonable value range of RMB 236.91-276.39 per share [10]